Erratum
to the article ‘Assessment of the GenoType MTBDRplus assay for rifampin and isoniazid resistance detection on sputum samples in Côte d’Ivoire’ by K. N’guessan*, J. S. Assi, T. Ouassa, J. M. Ahui-Brou, A. Tehe, M. Keita Sow, A. Guei, J. Kouakou, and M. Dosso in (Eur J Microbiol Immunol (Bp) 2014;4(3):166–173. , DOI: 10.1556/EuJMI-D-14-00014).
Authors would like to correct the article as follows:
1. Author affiliation No. 6 correctly reads as:
6 Programme National de Lutte contre la Tuberculose, Côte d’Ivoire
2. An error was made in Table 2 on p. 169 in column 4, rows 14–18. Please find below Table 2 with the proper values:
Table 2.
Patterns of GenoType MTBDRplus in comparison to drug susceptibility testing
| Number of sputum samples (%) | DST |
MTBDRplus assay |
Results | |||
|---|---|---|---|---|---|---|
| RMP | INH | RMP
pattern (rpoB) |
INH pattern |
|||
| katG | inhA | |||||
| 8 (6.7%) | R | R | ΔWT3,4, Mut1 (D516V) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3B (T8A) | MDR |
| 8 (6.7%) | R | R | ΔWT3,4, Mut1 (D516V) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 5 (4.2%) | R | R | ΔWT3,4, Mut1 (D516V) | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | R | R | ΔWT2,3,4 | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | R | R | ΔWT2 | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 4 (3.3%) | R | R | ΔWT7, Mut2B (H526D) | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | S | R | ΔWT7, Mut2B (H526D) | ΔWT, Mut1 (S315T) | WT | MDR |
| 2 (1.7%) | R | R | ΔWT7, Mut2B (H526D) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 6 (5%) | R | R | ΔWT7, Mut2A (H526Y) | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | S | S | ΔWT7, Mut2A (H526Y) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 3 (2.5%) | R | R | ΔWT7 | ΔWT, Mut1 (S315T) | WT | MDR |
| 11 (9.2%) | R | R | ΔWT7, Mut2A (H526Y) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | MDR |
| 2 (1.7%) | R | R | ΔWT7, Mut2A (H526Y) | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3B (T8A) | MDR |
| 4 (3.3%) | R | R | ΔWT8, Mut3 (S531L) | ΔWT, Mut1 (S315T) | WT | MDR |
| 2 (1.7%) | R | R | ΔWT8, Mut3 (S531L) | WT | WT | Rif monoR |
| 1 (0.8%) | S | S | ΔWT8, Mut3 (S531L) | WT | WT | Rif monoR |
| 1 (0.8%) | S | S | ΔWT8, Mut3 (S531L) | ΔWT, Mut1 (S315T) | WT | MDR |
| 2 (1.7%) | R | R | ΔWT8, Mut3 (S531L) | ΔWT, Mut1 (S315T) | WT | MDR |
| 11 (9.2%) | S | S | ΔWT8 | WT | WT | Rif monoR |
| 3 (2.5%) | R | R | ΔWT8 | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3B (T8A) | MDR |
| 1 (0.8%) | R | R | ΔWT8 | ΔWT, Mut1 (S315T) | WT | MDR |
| 1 (0.8%) | R | R | ΔWT8 | WT | ΔWT 1, Mut1 (C15T) | MDR |
| 27 (22.5%) | S | S | WT | WT | WT | Susceptible |
| 9 (7.5%) | S | R | WT | ΔWT, Mut1 (S315T) | WT | Inh monoR |
| 2 (1.7%) | S | R | WT | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3B (T8A) | Inh monoR |
| 2 (1.7%) | S | R | WT | WT | WT | Susceptible |
| 1 (0.8%) | S | R | WT | ΔWT, Mut1 (S315T) | ΔWT 2, Mut3A (T8C) | Inh monoR |
| Δ: Absence of hybridization signal with wild-type probes; WT: wild-type; Mut: mutation; DST: drug susceptibility testing; RMP: rifampin; INH: isoniazid; R: resistant; S: susceptible; MDR: multidrug-resistant; Rif monoR: rifampin monoresistant; Inh monoR: isoniazid monoresistant | ||||||
3. Table 3 on p. 170 was erroneously given with a dividing line, the corrected Table 3 can be found below:
Table 3.
Performance of MTBDRplus compared to drug susceptibility testing
| Drug susceptibility testing | Performances | ||
|---|---|---|---|
| Rifampin | 64 | 15 | Sensitivity: 100% (75.6–100%) |
| Specificity: 73.2% (61.3–84%) | |||
| PPV: 81% (72–90%) | |||
| 0 | 41 | NPV: 100% (69–100%) | |
| 75 | 2 | Sensitivity: 95% (90–99%) | |
| Isoniazid | Specificity: 95.1% (88.5–100%) | ||
| 4 | 39 | PPV: 97.4% (94–100%) | |
| NPV: 90.7% (82–99%) | |||
| PPV: positive predictive value; NPV: negative predictive value | |||
Contributor Information
K. N’guessan, 1Institut Pasteur de Côte d’Ivoire, Laboratoire National de Référence de la Tuberculose, Côte d’Ivoire.
J. S. Assi, 1Institut Pasteur de Côte d’Ivoire, Laboratoire National de Référence de la Tuberculose, Côte d’Ivoire.
T. Ouassa, 2Centre de Diagnostic et de Recherche sur le SIDA, Côte d’Ivoire.
J. M. Ahui-Brou, 3Service de Pneumologie CHU de Cocody, Côte d’Ivoire.
A. Tehe, 4Projet Retro-CI/CDC, Côte d’Ivoire.
M. Keita Sow, 5American Society for Microbiology, USA.
A. Guei, 1Institut Pasteur de Côte d’Ivoire, Laboratoire National de Référence de la Tuberculose, Côte d’Ivoire.
J. Kouakou, 6Programme National de Lutte contre la Tuberculose, Côte d’Ivoire.
M. Dosso, 1Institut Pasteur de Côte d’Ivoire, Laboratoire National de Référence de la Tuberculose, Côte d’Ivoire.